A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. - Chitty JL; Yam M; Perryman L; Parker AL; Skhinas JN; Setargew YFI; Mok ETY; Tran E; Grant RD; Latham SL; Pereira BA; Ritchie SC; et al. (Nature cancer, 2023)